...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Phase 3 BETonMACE Trial is Now Completed. Cognition and CKD Sub-Study Results to be Announced Soon.

Free
Message: Re: Insider Selling
4
Jul 11, 2019 08:20PM

Jul 11, 2019 08:44PM
3
Jul 11, 2019 09:10PM
3
Jul 11, 2019 09:14PM
4
Jul 11, 2019 09:17PM
4
Jul 11, 2019 09:38PM
1
Jul 12, 2019 07:24AM
2
Jul 12, 2019 08:28AM
1
Jul 12, 2019 11:26AM
3
Jul 12, 2019 11:55AM
2
Jul 12, 2019 12:25PM

Jul 12, 2019 08:33PM

Jul 12, 2019 08:47PM
4
Jul 13, 2019 12:09PM
3
Jul 13, 2019 01:31PM
5
Jul 13, 2019 04:59PM
1
Jul 13, 2019 05:00PM
4
Jul 13, 2019 05:06PM

CCD - Yes the company has been receiving some form of aggregate data once a week or once a month since the trial started. As noretreat said in his post at 5:06pm, blinded aggregate data can be very informative. It can tell us a lot, MACE rates, changes in certain biomarkers and many other data points that can be compared to "expected" and/or "placebo expected" several different ways. As noretreat stated, one has to be careful about trying to draw conclusions, but aggregate results are at the very least directional.

Now following on my previous post I will take a hypothetical situation; If the company was getting aggregate data on MOCA scores for example, and they had an average of 24 for the entire group of patients over 70 after recruitment and then after the third MOCA test was administered that aggregate number went up to 26 that would equate to around a 9% increase in cognitive function for the entire group of patients over 70 years old. It would suggest a direction of increased congnitive function. It would also be unheard of results as this has not be seen in any past cognition trials that I am aware of. Since there are no other drugs that I know of that increase cognitive function one could go even further and theorize that the placebo group would continue to get worse over time so the difference between dosed and placebo groups could be even greater in the example in this hypothetical situation.

Now whether tundup got his words mixed up by saying blinded data and should have said from data that the company receives is really the only point worth arguing. 

What we do know absolutely is that round the time that many patients in the trial would have been getting their third MOCA test(at the end of the second full year of dosing) is when the company started talking a lot about the cognition sub study. Is that a coincidence?, maybe but I am choosing to look at it from what I would consider a more realistic point of view.

Line up all of the news releases from the start of the trial until today and see if you can see a patern. You will have to insert presentations and articles in that lineup in the appropriate dates. In doing this you may come to a similar conclusion to what I did.

All IMO, dyodd

tada

4
Jul 13, 2019 09:06PM
4
Jul 13, 2019 10:16PM
3
Jul 13, 2019 10:28PM
4
Jul 14, 2019 05:43AM
4
Jul 14, 2019 10:30AM
9
Jul 14, 2019 01:09PM
3
Jul 14, 2019 02:05PM
1
Jul 14, 2019 10:35PM
1
Jul 15, 2019 01:04AM
Share
New Message
Please login to post a reply